Comparing Palvella Therapeutics (PVLA) & Its Rivals

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Palvella Therapeutics to similar companies based on the strength of its dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Insider and Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Palvella Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-235.83%	-32.89%

Earnings & Valuation

This table compares Palvella Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.62
Palvella Therapeutics Competitors	$9.96 billion	$135.48 million	-8.31

Palvella Therapeutics’ rivals have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and price targets for Palvella Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8194	21885	49779	1316	2.54

Palvella Therapeutics presently has a consensus target price of $40.33, indicating a potential upside of 106.31%. As a group, “Pharmaceutical preparations” companies have a potential upside of 207.38%. Given Palvella Therapeutics’ rivals higher probable upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its rivals.

Volatility and Risk

Palvella Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ rivals have a beta of 3.64, suggesting that their average share price is 264% more volatile than the S&P 500.

Summary

Palvella Therapeutics rivals beat Palvella Therapeutics on 8 of the 13 factors compared.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.